Understanding Rheumatoid Arthritis Before and After TNF or JAK Inhibitor Treatment

-

 

  Image credit: https://openai.com/index/dall-e/  


Rheumatoid arthritis, or RA as it's often called, is a condition where your body's immune system mistakenly attacks the lining of your joints, causing pain, swelling, and stiffness. Many people with RA find that their symptoms can be managed with medications called TNF or JAK inhibitors. These drugs help to calm down the overactive immune system in the joints. However, some patients still don't respond well to these treatments, and doctors are always looking for better ways to understand and treat this condition.

This new piece of research has taken a really close look at the fluid inside the joints of people with RA, known as synovial fluid or SF. The scientists used a clever technique called single-cell RNA sequencing (scRNA-seq). This allows them to study the individual cells present in the SF and see what genes they are switching on and off. By doing this before and after patients received TNF or JAK inhibitor treatment (specifically adalimumab or tofacitinib), the researchers hoped to understand how these drugs work at a cellular and molecular level. They also compared the SF from RA patients with that from people who had osteoarthritis (OA), a different type of joint problem.

Key immune cells in RA synovial fluid: The study identified several types of immune cells in the SF of RA patients, including macrophages, dendritic cells (DCs), and T cells. Interestingly, in RA patients, macrophages were the most common type of cell found in the SF. The researchers then went a step further and identified different subtypes of these macrophages. Two particular types, called SPP1+ macrophages and S100A12+ macrophages, seemed to be very active in RA.
  • SPP1+ macrophages were found in high numbers in RA patients, and their levels decreased after treatment. The amount of SPP1+ macrophages also seemed to be linked to how severe a patient's RA was. This suggests that these cells play a significant role in driving the inflammation in RA.
  • S100A12+ macrophages were another inflammatory type of macrophage found in the SF of RA patients.

How these cells cause inflammation: The researchers discovered that these SPP1+ and S100A12+ macrophages can communicate directly with other immune cells, particularly a type of T cell called CXCL13+CD4+ T cells. This communication seems to fuel the inflammation in the joints. For example, SPP1+ macrophages and CXCL13+CD4+ T cells showed a lot of interaction, and this interaction was reduced after the patients received treatment.
To further investigate this, the scientists even did some experiments in the lab. They took these specific types of macrophages from the SF of RA patients and mixed them with fibroblast-like synoviocytes (FLS), which are cells found in the joint lining that contribute to RA. They found that both SPP1+ and S100A12+ macrophages could stimulate the FLS to produce more inflammatory molecules. This suggests that these macrophages directly contribute to the damaging inflammation in the RA joint. They even tested what happened when they reduced SPP1 in mice with a condition similar to RA and found that it reduced the expression of RA-related inflammatory substances.

The impact of RA drugs: The study also looked at how the TNF inhibitor adalimumab and the JAK inhibitor tofacitinib affected these cells. They found that both drugs could reduce the density of the harmful SPP1+ macrophages and alter the genes expressed by these cells. The communication between SPP1+ macrophages and CXCL13+CD4+ T cells was also diminished after treatment with both drugs.
However, there were some differences observed between the two drugs. For instance, tofacitinib seemed to be more effective at reducing the signs of exhaustion in the CXCL13+CD4+ T cells. The researchers also tracked the changes in SPP1+ macrophages over time during tofacitinib treatment and found that the drug might block certain inflammatory pathways in patients who didn't respond as well.

Synovial fluid as a window into the joint: Traditionally, studying RA has involved looking at samples of the synovial tissue, which requires a biopsy. This study suggests that the synovial fluid can also provide valuable information about what's happening in the joint. The researchers found that the harmful SPP1+ macrophages were abundant in both the SF and the ST but were hardly found in the blood. This indicates that analysing SF could be a less invasive way to monitor the disease and how well treatments are working.

What this means for RA: This research provides a more detailed understanding of the specific immune cells and their interactions that drive inflammation in RA. By identifying key players like SPP1+ macrophages and the communication between them and CXCL13+CD4+ T cells, the study highlights potential targets for future treatments. The findings also suggest that the effectiveness of different RA drugs like adalimumab and tofacitinib might involve slightly different ways of affecting these cells and pathways.

Important considerations: It's worth noting that this study had a relatively small number of patients, so these findings will need to be confirmed in larger groups. Also, the post-treatment samples were taken after only one month, so it would be interesting to see if these changes persist over longer periods. Additionally, SF is not always easily obtainable from all RA patients, which could limit the broad application of these findings.

In conclusion: Overall, this study sheds valuable light on the complex immune environment within the joints of people with rheumatoid arthritis. By using advanced single-cell technology, the researchers have identified key cell types and communication pathways that contribute to the disease and are affected by common RA treatments. This research moves us closer to understanding the individual differences in RA and could pave the way for more personalised and effective treatment strategies in the future.
 
 
Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment. Nature Communications (2025). https://www.nature.com/articles/s41467-025-57361-0#Sec2

Journal information: https://www.nature.com/ncomms/

 

Location: Oxford, UK

Comments

  1. Yue Wang14 April 2025 at 10:03

    This article has done many experiments. Here are my thoughts about this work. First, synovial fluid are less invasive to get compared to synovial tissue biopsy. However, there is some difference between SF and ST. For example, fibroblast plays a key role in pathogenesis in RA. But in this article, the number of fibroblasts in SF only share a small part through scRNA-seq. Second, though only 6 RA patients are included in this article, they gave a persuasive outcome by comparing pre and post- treatment change in each patient. Third, they conducted cell experiments by co-culture and animal experiments through CRISPR/Cas9 based conditional knockout mice to support their findings. In summary, there are a lot of work and it may take several years.

    ReplyDelete

Post a Comment

Popular posts from this blog

Unlocking insights: simplifying single-cell data with Strand’s scRNA portal

-
Image
Image credit:   https://scrna-curation.mystrand.org/ Simplifying single-cell data exploration with Strand’s scRNA portal In the rapidly advancing world of single-cell RNA sequencing (scRNA-seq), navigating complex datasets can be a major challenge. Strand’s scRNA Portal is designed to transform this challenge into an opportunity by harmonizing publicly available datasets, making disease-specific omics data accessible, actionable, and ready for discovery. Why strand’s scRNA portal was built 1) Focus on unmet needs in key diseases Starting with datasets with diseases with significant unmet clinical need: Inflammatory bowel disease :  Covering Ulcerative Colitis and Crohn’s Disease. Neurodegenerative disorders :  Including Alzheimer’s Disease, Parkinson’s Disease and Frontotemporal Dementia. 2)  The rise of scRNA-seq in aiding precision medicine:  Single-cell RNA sequencing provides unprecedented insights into cellular heterogeneity, which is pivotal for identifyi...
Read more

Understanding Your Immune System: A Lifespan Journey

-
Image
Image credit:   https://openai.com/index/dall-e/   Have you ever wondered how your immune system changes as you get older? It’s not just about catching colds, our immune system is always working hard to protect us and it’s constantly evolving throughout our lives. A new study has looked at how our immune system changes from birth right through to old age, providing some fascinating insights. What the study did : Scientists looked at blood samples from a large group of healthy people, ranging from newborns to those over 90 years old. They used advanced techniques to study the different types of immune cells in these samples. They looked at how these cells behave and change over time. This is called a "single-cell atlas," because they looked at each cell individually. Key findings Immune cells change over time: The study identified 25 different types of immune cells in the blood. The number of each type of cell changes throughout life. Some become more commo...
Read more

Cracking the code of itchy skin: A new way to diagnose and treat skin problems

-
Image
a : The ridgeline plots show the activity scores of different immune response types (Th1, Th2, Th17, type I interferon, neutrophil-related, macrophage-related, and eosinophil-related responses) in skin samples from different inflammatory skin diseases (Psoriasis, Atopic Dermatitis, Lichen Planus, Cutaneous Lupus Erythematosus, Neutrophilic Dermatosis, and Wells Syndrome). The solid lines mark the point where each response type is considered active. b : Box plots compare the immune response scores in skin samples across all these diseases for the "sentinel" (reference) biopsies. Each dot is one sample. The number of samples for each condition is listed: Psoriasis (25), Atopic Dermatitis (16), etc., along with healthy controls (8). c : Box plots show the immune response scores for "test" samples (a different set of biopsies). Sample numbers for each disease are also listed, like Psoriasis (8) and Atopic Dermatitis (15). b–c : In the box plots, the middle line shows th...
Read more